INFORMAZIONI SU QUESTO ARTICOLO

Cita

1. Mikhailov TA, Furner SE. Breastfeeding and genetic factors in the etiology of inflammatory bowel disease in children. World J Gastroenterol. 2009;15:270-9.10.3748/wjg.15.270 Search in Google Scholar

2. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. 2004;3:394-400. Search in Google Scholar

3. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-29.10.1056/NEJMra020831 Search in Google Scholar

4. Baumgart DC, Sandborn WJ, Inflammatory bowel disease: clinical aspects and established and evolving treatments. The Lancet. 2007;369(9573):1641-57.10.1016/S0140-6736(07)60751-X Search in Google Scholar

5. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280-8.10.3748/wjg.14.4280273117718666314 Search in Google Scholar

6. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al., Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35-40.10.1016/j.jpeds.2004.08.04315644819 Search in Google Scholar

7. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596-604.10.1038/ng2032275793917435756 Search in Google Scholar

8. Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn‘s disease. World J Gastroenterol. 2012;18(2):105-18.10.3748/wjg.v18.i2.105325743722253516 Search in Google Scholar

9. Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T, Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol. 2015;21(29):8776-86.10.3748/wjg.v21.i29.8776452802026269667 Search in Google Scholar

10. Zhang X, Song L, Li L, Zhu B, Huo L, Hu Z, et al. Phosphatidylserine externalized on the colonic capillaries as a novel pharmacological target for IBD therapy. Sig Transduct Target Ther. 2021;6:235.10.1038/s41392-021-00626-z820621234131110 Search in Google Scholar

11. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4),590-9. Search in Google Scholar

12. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104(10):2524-33.10.1038/ajg.2009.32219532125 Search in Google Scholar

13. Clark WM, Hazel JS, Coull BM. Lazaroids. Drugs. 1995;50:971-83.10.2165/00003495-199550060-00005 Search in Google Scholar

14. De Oca J, Guadrado S, Vallet J, Banasco C, Martin E, Ardanuy C, et al. Protective effects of lazaroid U74389G on intestinal graft after heterotopic small bowel transplantation in rats. J Sur Res. 1998;75(1):18-23.10.1006/jsre.1997.5244 Search in Google Scholar

15. Kavanagh RJ, Kam PCA Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth. 200;86(1):110-19.10.1093/bja/86.1.110 Search in Google Scholar

16. Cahill L, Hall ED. Is it time to resurrect “Lazaroids”? J Neurosci Res. 2017;95:17-20. Search in Google Scholar

17. Chalasti M, IordanouC, Kratiras Z, Stylianaki A, Trigka E-A, Lakiotaki E, et al. Experimental isolation and preservation of solid organs before transplantation: effects of pretreatment using four different molecules. J Int Med Res. 2020;48(6):1-19.10.1177/0300060520933452 Search in Google Scholar

18. Morris GP, Beck PL, Herridge MS, Depew W, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat. Gastroenterol. 1989; 96:795-803.10.1016/0016-5085(89)90904-9 Search in Google Scholar

19. Wallace JL, Le T, Carter L, Appleyard CB, Beck PL. Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods. 1995;33(4):237-9.10.1016/1056-8719(95)00001-X Search in Google Scholar

20. Stavreva G, Shopova V, Dancheva V, Stoynova A, Terziev L. Effect of 21-aminosteroid U-74389G on markers for pneumotoxicity in rat bronchoalveolar lavage flid after intratracheal amiodarone administration. J Biomed Clin Res. 2008;1(1):30-9. Search in Google Scholar

21. Stavreva GT, Dancheva VY, Terziev LG, Krastev PK. Effects of 21-aminosteroid U-74389G on amiodarone-induced pulmonary toxicity in rats. Arch Balk Med Union. 2019;54(3):404-10.10.31688/ABMU.2019.54.3.01 Search in Google Scholar

22. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther. 2007;322:435-42.10.1124/jpet.107.12276217488880 Search in Google Scholar

23. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22(4):558-74.10.5056/jnm16001505656627431236 Search in Google Scholar

24. Piechota-Polanczyk A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(7):605-20.10.1007/s00210-014-0985-1406533624798211 Search in Google Scholar

25. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012;(60):3678.10.3791/3678 Search in Google Scholar

26. Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280-8.10.3748/wjg.14.4280 Search in Google Scholar

27. Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenteroi. 2000; 6(4):483-9. Search in Google Scholar

28. Hayashi R, Wada H, Ito K, Adcock I. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004;500(1-3):51-62.10.1016/j.ejphar.2004.07.011 Search in Google Scholar

29. Braughler JM, Chase RL, Neff GL, Yonkers PA, Day JS, Hall ED, et al. A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells. J Pharmacol Exp Ther. 1988;244(2):423-7. Search in Google Scholar

30. Jacobsen EJ, McCall JM, Ayer DE, Van dootnik FJ, Palmer JR, Belonga KL, et al. Novel 21-aminosteroids that inhibit iron-dependent peroxidation and protect against nervous system trauma. Journal of Medicinal Chemistry. 1990;33(4): 1145-51.10.1021/jm00166a010 Search in Google Scholar

31. Hall ED, Mccall JM, Means ED. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol. 1994;28:221-68.10.1016/S1054-3589(08)60497-4 Search in Google Scholar

32. Muller TB, Haraldseth O, Jones R.A., et al. Perfusion and diffusion-weighted MR images for in vivo evaluation of treatment with U74389G in a rat stroke model. Stroke 1995; 26(8):1453-8.10.1161/01.STR.26.8.1453 Search in Google Scholar

33. Fabian RH, Dewitt DS, Kent TA. The 21-aminosteroid U-74389G reduces cerebral superoxide anión concentration following fluid percussion injury of the brain. J neurotrauma. 1998;15(6):433-40.10.1089/neu.1998.15.433 Search in Google Scholar

34. Shi F, Cavitt J, Audus KL. 21-aminosteroid and 2-(aminomethyl) chromans inhibition of arachidonic acid-induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Free Radie Biol Med. 1995; 19(3):349-57.10.1016/0891-5849(95)00049-4 Search in Google Scholar

35. Antonini JM, Van DK, Dimatteo M, Rea Sor MJ. Attenuation of acute inflammatory effects of silica in rat lung by 21-aminosteroid, U74389G. Inflammation. 1995; 19(1):9-21.10.1007/BF015343767705890 Search in Google Scholar

36. Remmers D, Wenger A, Grotz M, Seekamp A, Pape HC, Gruner A, et al. Attenuation of mutliple organ dysfunction in a chronic sheep model by the 21-aminosteroid U74389G. J Surg Res. 1996;62(2):278-83.10.1006/jsre.1996.02088632652 Search in Google Scholar

37. Huang H, Patel PB, Salahudeen AK. Lazaroid compounds prevent early but not late stages of oxidant-induced cell injury: potential explanation for the lack of efficacy of lazaroids in clinical trials. Pharmacol Res. 2001;43(1):55-61.10.1006/phrs.2000.074011207066 Search in Google Scholar

38. Kawarski M, Thomas K Hagerman TK, Caitlin E Karver CE. Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1. Chem Biol Drug Des. 2015; 86(5):1049-54.10.1111/cbdd.1257225871734 Search in Google Scholar

eISSN:
1313-9053
Lingua:
Inglese
Frequenza di pubblicazione:
2 volte all'anno
Argomenti della rivista:
Medicine, Clinical Medicine, other, Ophthalmology, Public Health, Pharmacy, Clinical Pharmacy